DR. MARK S. RUBIN M.D. NPI 1033192570

NPI Details

DR. Mark S. Rubin, M.D. is a medical oncology internal medicine in Bonita Springs, FL with 38 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Mark S. Rubin, M.D. NPI is 1033192570. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS
Graduation Year:1988

The provider's business location address is:

9776 BONITA BEACH RD SE
#201A
BONITA SPRINGS, FL
ZIP 34135-773
Phone: (239) 947-3092
Fax: (239) 947-1077

The NPI 1033192570 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Ferritin (blood protein) level (HCPCS:82728)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Magnesium level (HCPCS:83735)
• Iron level (HCPCS:83540)
• Protein measurement, serum (HCPCS:84165)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Iron binding capacity (HCPCS:83550)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Injection of drug or substance into vein (HCPCS:96374)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Blood test, clotting time (HCPCS:85610)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Automated urinalysis test (HCPCS:81003)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Uric acid level, blood (HCPCS:84550)
• Folic acid level, serum (HCPCS:82746)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Phosphate level (HCPCS:84100)
• Urinalysis, manual test (HCPCS:81002)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Testosterone (hormone) level, total (HCPCS:84403)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Drawing of blood for a medical problem (HCPCS:99195)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Hepatitis b core antibody measurement (HCPCS:86704)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Detection test by immunoassay technique for hepatitis b surface antigen (HCPCS:87340)
• Red blood count, manual test (HCPCS:85044)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Hepatitis b core antibody (igm) measurement (HCPCS:86705)
• Red blood count, automated test (HCPCS:85045)
• Erythropoietin (protein) level (HCPCS:82668)

The enumeration date for this NPI number is 11/29/2005 and was last updated on 9/1/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.